Wall Street analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to post earnings per share of ($1.74) for the current quarter, according to Zacks. Seven analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($1.57) and the lowest estimate coming in at ($1.86). Ultragenyx Pharmaceutical posted earnings of $0.62 per share in the same quarter last year, which suggests a negative year over year growth rate of 380.6%. The firm is expected to announce its next earnings report on Monday, May 6th.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($6.79) per share for the current financial year, with EPS estimates ranging from ($7.48) to ($6.00). For the next financial year, analysts expect that the company will post earnings of ($4.99) per share, with EPS estimates ranging from ($5.73) to ($3.77). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.01. Ultragenyx Pharmaceutical had a negative net margin of 383.75% and a negative return on equity of 35.26%. The business had revenue of $16.26 million for the quarter, compared to analyst estimates of $13.30 million.
Institutional investors have recently made changes to their positions in the business. Alliancebernstein L.P. grew its holdings in shares of Ultragenyx Pharmaceutical by 5.4% in the 3rd quarter. Alliancebernstein L.P. now owns 992,357 shares of the biopharmaceutical company’s stock worth $75,757,000 after purchasing an additional 50,489 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Ultragenyx Pharmaceutical by 5.3% in the 3rd quarter. Wells Fargo & Company MN now owns 23,742 shares of the biopharmaceutical company’s stock worth $1,812,000 after purchasing an additional 1,194 shares during the last quarter. Capital Impact Advisors LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 31.7% in the 4th quarter. Capital Impact Advisors LLC now owns 37,858 shares of the biopharmaceutical company’s stock worth $1,585,000 after purchasing an additional 9,112 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $1,954,000. Finally, Kiwi Wealth Investments Limited Partnership bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $958,000. 99.20% of the stock is currently owned by hedge funds and other institutional investors.
RARE stock traded down $2.14 on Thursday, reaching $65.80. 408,232 shares of the company were exchanged, compared to its average volume of 662,824. Ultragenyx Pharmaceutical has a 12 month low of $37.44 and a 12 month high of $90.98. The firm has a market capitalization of $3.48 billion, a P/E ratio of -8.90 and a beta of 2.21.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Featured Story: Net Asset Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.